P81 Long-term efficacy of abrocitinib in adolescents and adu…
Emerging
3
Citations0
Refs2023
Year
Search Works
Work Details
- DOI 10.1093/bjd/ljad113.109
- OpenAlex ID W4382025425
- Type Conference-abstract
- Language EN
- Published 01 Jun 2023
- Volume 188 (Supplement_4)
- Source British Journal of Dermatology
- Publisher Oxford University Press
- Countries 4
- Institutions 10
- Added 27 Jun 2023
- Updated 29 Oct 2026
External Links
MENU
0
P81 Long-term efficacy of abrocitinib in adolescents and adults with moderate-to-severe atopic dermatitis: a post hoc analysis of JADE EXTEND
Conference-abstract 2023 EN Bronze
Abstract Differences exist in the manifestation and disease course of atopic dermatitis (AD) between adult and adolescent patients. Long-term efficacy of abrocitinib (an oral, once-daily Janus kinase 1-selective inhibitor) was examined in the phase III extension study JADE EXTEND (NCT03422822). This interim post hoc analysis assessed abrocitinib treatment efficacy up to 96 weeks in adolescents and…
3
Citations
0
References
10
Authors
0.00
FWCI
Citations by Year
Last 3 yearsTopics
Keywords
UN Sustainable Development Goals
1 SDGsAuthors & Affiliations
10 authors| # | Author | Institutions | ORCID |
|---|---|---|---|
| 1 | Amy S. Paller | Northwestern University (US) | |
| 2 | Michael J. Cork | Sheffield Children's Hospital (GB) University of Sheffield (GB) | |
| 3 | Carsten Flohr | King's College London (GB) Guy's and St Thomas' NHS Found… (GB) | |
| 4 | Christine Bangert | Medical University of Vienna (AT) | |
| 5 | Stephan Weidinger | University Hospital Schleswig-… (DE) | |
| 6 | John Nesnas | Pfizer (United Kingdom) (GB) | |
| 7 | Saleem A. Farooqui | Pfizer (United Kingdom) (GB) | — |
| 8 | Pinaki Biswas | Pfizer (United States) (US) | |
| 9 | Melissa Watkins | Pfizer (United States) (US) | |
| 10 | Herwig Koppensteiner | Pfizer (Austria) (AT) |
Related Works
10Data: OpenAlex